Business Context and Reporting Period
This Form 8-K Current Report from Arrivent Biopharma, Inc. (AVBP) covers the 2025 Annual Meeting of Stockholders held on June 18, 2025. The company is an emerging growth company incorporated in Delaware, with its principal executive offices in Newtown Square, PA.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance events and does not contain financial performance data.
Material Changes and Voting Results
The primary event reported is the outcome of the Annual Meeting. A quorum of 25,159,248 shares (73.89% of eligible shares) was present out of 34,045,193 shares eligible to vote.
1. Election of Directors
- Zhengbin (Bing) Yao, Ph.D.: Elected as a Class I director for a three-year term. Received 22,116,332 votes "For" and 442,833 votes "Withheld". There were 2,600,083 broker non-votes.
- Kristine Peterson: Elected as a Class I director for a three-year term. Received 21,932,842 votes "For" and 626,323 votes "Withheld". There were 2,600,083 broker non-votes.
2. Auditor Ratification
- Stockholders ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- Votes cast: 24,991,469 "For", 242 "Against", and 167,537 "Abstaining". There were 0 broker non-votes.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on business outlook, specific risks, contingencies, or unusual items. For further details on these matters, the filing references the definitive proxy statement on Schedule 14A filed on April 28, 2025.
Investor Verification Checklist
- Verify the terms of the newly elected directors (Zhengbin Yao and Kristine Peterson) and their independence status in the Schedule 14A proxy statement.
- Confirm the scope of the audit engagement with PricewaterhouseCoopers LLP for the 2025 fiscal year.
- Review the Schedule 14A filed on April 28, 2025, for detailed management discussion and financial context not included in this 8-K.
- Note the significant number of broker non-votes (2,600,083) on the director elections, indicating shares held in street name where brokers did not have discretionary voting authority.